REGISTER
MedJ at ESMO 2025 with Dr. Nicoletta Colombo
New research helps clarify the debate around MedJ at ESMO 2025 with Dr. Nicoletta Colombo. It pulls together the main findings on ESMO, ENGOT, PFS and shows what they may mean for diagnosis, monitoring, prevention, or treatment.

Nicoletta Colombo, European Institute of Oncology, Milan, Italy

Provided an on-site interpretation of the ENGOT-ov65 study at ESMO: Pembrolizumab combined with bevacizumab and chemotherapy significantly improved progression-free survival (PFS) in advanced ovarian cancer, with a manageable safety profile, offering new evidence for first-line immunotherapy in ovarian cancer!

0
0
Loading